DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Feagan BG, Sandborn WJ, D’Haens G. et al.
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohnʼs disease: a randomised, double-blind, placebo-controlled phase 2 study.
Lancet 2017;
389: 1699-1709
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.